Akebia Therapeutics Inc (AKBA): Vadadustat: First Approval Anthony Ma...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	481
Posts	60471
Boards Moderated	18
Alias Born	09/20/2001

XenaLives

Re: None

Friday, 07/09/2021 6:03:10 AM

Friday, July 09, 2021 6:03:10 AM

Vadadustat: First Approval
Anthony Markham 1
Affiliations expand
PMID: 32852744 DOI: 10.1007/s40265-020-01383-z
Abstract
Vadadustat (VAFSEO®) is a prolyl hydroxylase inhibitor being developed by Akebia Therapeutics, Inc. (Akebia) for the treatment of anaemia associated with chronic kidney disease (CKD). Akebia is collaborating with Mitsubishi Tanabe Pharma Corporation on the development and commercialization of vadadustat in Japan and with Otsuka Pharmaceutical Co. Ltd on the development and commercialization of vadadustat in the USA, the EU and certain other territories. The drug is approved in Japan for use in adult patients with anaemia associated with CKD and regulatory submissions are planned in the USA and the EU. This article summarizes the milestones in the development of vadadustat leading to this first approval.

https://pubmed.ncbi.nlm.nih.gov/32852744/